Pneumonia treatments

While there’s no sure way to prevent pneumonia, there are a number of steps you can take to reduce your risk of infection. There are also proven methods for treating the various types of pneumonia, once properly diagnosed. Because pneumonia comes in different forms, treatment plans vary widely. Some people may only need bed rest, while others may require hospitalization. Roughly one-third of all pneumonia cases in this country are caused by respiratory viruses, most commonly Your doctor will outline a plan that’s specific to you, considering the type of pneumonia you have, the severity of the condition, your age, and your overall health. From there, you’ll know whether you can be treated at home or at the hospital, and whether or not you need antibiotics. ( Early Certain drugs can also effectively treat fungal pneumonia. Medication is usually ineffective in treating the viral types of pneumonia — doctors will instead treat the symptoms — though these infections also tend to be milder and clear up on their own. Working closely with your doctor and following all directions will speed your recovery. People who are very old, very young, have Mycoplasmal pneumonia is caused by Mycoplasma pneumoniae, which was originally thought to be a virus or a fungus, but has since been classified as a bacteria. ( People with more severe cases of bacterial pneumonia may be treated with oxygen, intravenous fluids, and breathing treatments to ease symptoms. If the course of the pneumonia is sl...

Eagle Pharmaceutics Inc. +6.88% said Wednesday it has won Food and Drug Administration Qualified Infectious Disease Product (QDIP) and Fast-Track Designation for CAL02, a treatment for severe community-acquired bacterial pneumonia (SCABP) as an add-on therapy to standard of care. The former designation will entitle the company to an additional eight to 10 years of regulatory exclusivity if the product is approved. Eagle also believes CAL02 is a new chemical entity, which would result in five years of marketing exclusivity. The latter underscores the significant unmet medical need in treating SCABP, a global illness that is associated with high morbidity and mortality, despite the availability of vaccines and antibiotics. Woodcliff Lake, N.J.-based Eagle is currently evaluating CAL02 in a Phase 2 trial where it’s being administered intravenously in addition to standard of care. The trial aims to enroll about 2l76 patients with SCABP worldwide. The QIDP designation was created in 2012 to encourage the development of treatments for antibiotic-resistant organisms known to cause serious or life-threatening infections. The stock has fallen 36% in the year to date, while the S&P 500 has gained 11%.